JUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody

Stock News07-02

JUNSHI BIO (HKG: 01877) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million.

The significant move follows the company's announcement of a licensing agreement. On June 30, 2026, the company entered into an Authorization License Agreement with its counterparty.

Details of the Strategic Deal

Under the terms of the agreement, JUNSHI BIO has granted exclusive rights for the development, registration, production, and commercialization of the collaboration product, known as nuokaoqi bai dan kang (JS005, an anti-IL-17A monoclonal antibody), within the Greater China region. This region encompasses mainland China, Hong Kong, Macau, and Taiwan.

Financial Terms and Milestones

As part of the deal, JUNSHI BIO will receive an upfront payment of RMB 215 million, which is non-deductible and non-refundable. Furthermore, the company is eligible to receive development and sales milestone payments that could total up to RMB 1.125 billion. Additionally, JUNSHI BIO will earn tiered royalties based on a double-digit percentage of the net sales generated in the Greater China region.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108387678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108387678","market":"sh","top_or_hot":-1,"title":"JUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody","media":"Stock News","content":"<p><b>JUNSHI BIO</b> (<b>HKG: 01877</b>) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million.<br><br>\nThe significant move follows the company's announcement of a licensing agreement. On June 30, 2026, the company entered into an Authorization License Agreement with its counterparty.<br><br>\n<b>Details of the Strategic Deal</b><br><br>\nUnder the terms of the agreement, <b>JUNSHI BIO</b> has granted exclusive rights for the development, registration, production, and commercialization of the collaboration product, known as nuokaoqi bai dan kang (JS005, an anti-IL-17A monoclonal antibody), within the Greater China region. This region encompasses mainland China, Hong Kong, Macau, and Taiwan.<br><br>\n<b>Financial Terms and Milestones</b><br><br>\nAs part of the deal, <b>JUNSHI BIO</b> will receive an upfront payment of RMB 215 million, which is non-deductible and non-refundable. Furthermore, the company is eligible to receive development and sales milestone payments that could total up to RMB 1.125 billion. Additionally, <b>JUNSHI BIO</b> will earn tiered royalties based on a double-digit percentage of the net sales generated in the Greater China region.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>JUNSHI BIO</b> (<b>HKG: 01877</b>) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million.<br><br>\nThe significant move follows the company's announcement of a licensing agreement. On June 30, 2026, the company entered into an Authorization License Agreement with its counterparty.<br><br>\n<b>Details of the Strategic Deal</b><br><br>\nUnder the terms of the agreement, <b>JUNSHI BIO</b> has granted exclusive rights for the development, registration, production, and commercialization of the collaboration product, known as nuokaoqi bai dan kang (JS005, an anti-IL-17A monoclonal antibody), within the Greater China region. This region encompasses mainland China, Hong Kong, Macau, and Taiwan.<br><br>\n<b>Financial Terms and Milestones</b><br><br>\nAs part of the deal, <b>JUNSHI BIO</b> will receive an upfront payment of RMB 215 million, which is non-deductible and non-refundable. Furthermore, the company is eligible to receive development and sales milestone payments that could total up to RMB 1.125 billion. Additionally, <b>JUNSHI BIO</b> will earn tiered royalties based on a double-digit percentage of the net sales generated in the Greater China region.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1108387678","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108387678","pubTimestamp":1782955831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JUNSHI BIO (HKG: 01877) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million. The significant move...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01877":"君实生物","BK1583":"高瓴概念","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK1515":"抗疫概念"},"translate_title":"君实生物股价因新型抗体许可协议飙升逾11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1,"VXUS":1},"content_text":"JUNSHI BIO (HKG: 01877) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million.\nThe significant move follows the company's announcement of a licensing agreement. On June 30, 2026, the company entered into an Authorization License Agreement with its counterparty.\nDetails of the Strategic Deal\nUnder the terms of the agreement, JUNSHI BIO has granted exclusive rights for the development, registration, production, and commercialization of the collaboration product, known as nuokaoqi bai dan kang (JS005, an anti-IL-17A monoclonal antibody), within the Greater China region. This region encompasses mainland China, Hong Kong, Macau, and Taiwan.\nFinancial Terms and Milestones\nAs part of the deal, JUNSHI BIO will receive an upfront payment of RMB 215 million, which is non-deductible and non-refundable. Furthermore, the company is eligible to receive development and sales milestone payments that could total up to RMB 1.125 billion. Additionally, JUNSHI BIO will earn tiered royalties based on a double-digit percentage of the net sales generated in the Greater China region.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108387678","isCrawlerRequest":true}